Celon Pharma S.A. (WSE:CLN)
Poland
· Delayed Price · Currency is PLN 22.70
+0.30 (1.34%)
May 23, 2025, 2:44 PM CET
Celon Pharma Revenue
Celon Pharma had revenue of 49.33M PLN in the quarter ending March 31, 2025, with 27.10% growth. This brings the company's revenue in the last twelve months to 213.98M, up 1.57% year-over-year. In the year 2024, Celon Pharma had annual revenue of 204.98M, down -4.18%.
Revenue (ttm)
213.98M
Revenue Growth
+1.57%
P/S Ratio
5.64
Revenue / Employee
384.86K
Employees
515
Market Cap
1.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 204.98M | -8.94M | -4.18% |
| Dec 31, 2023 | 213.92M | 20.04M | 10.33% |
| Dec 31, 2022 | 193.89M | -2.20M | -1.12% |
| Dec 31, 2021 | 196.09M | 38.64M | 24.54% |
| Dec 31, 2020 | 157.45M | 55.20M | 53.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 12.61B |
| Synektik Spólka Akcyjna | 556.63M |
| Voxel | 507.77M |
| Ryvu Therapeutics | 101.96M |
| Selvita | 359.79M |
| Centrum Medyczne ENEL-MED | 735.59M |
| EMC Instytut Medyczny | 809.41M |
| Scope Fluidics | 117.00K |
Celon Pharma News
- 2 months ago - Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease - Benzinga